Barclays raised the firm’s price target on Exelixis (EXEL) to $45 from $44 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and targets in the small and mid cap biotechnology group as part of a Q1 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
- Exelixis price target lowered to $43 from $46 at RBC Capital
- Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
- Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
- Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs